Last $2.32 USD
Change Today -0.06 / -2.52%
Volume 66.5K
CDXS On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/13/14 - $3.30
52 Week Low
12/24/13 - $1.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

125 Employees
Last Reported Date: 03/13/14
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $334.8K
Special Advisor
Total Annual Compensation: $68.8K
Compensation as of Fiscal Year 2013.

codexis inc (CDXS) Key Developments

Codexis, Inc. Appoints Kathleen Glaub to Board of Directors

Codexis, Inc. announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board. Ms. Glaub has recently been appointed as CEO of Afferent Pharmaceuticals, where she has been a member of its board of directors since 2013.

Codexis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Full Year 2014

Codexis, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues were $6,570,000 against $6,974,000 a year ago. Loss from operations was $8,911,000 against $12,450,000 a year ago. Loss before income taxes was $8,916,000 against $12,617,000 a year ago. Net loss was $8,479,000 or $0.22 basic and diluted per share against $12,605,000 or $0.33 basic and diluted per share a year ago. For the six months, the company's total revenues were $13,644,000 against $18,455,000 a year ago. Loss from operations was $15,307,000 against $22,080,000 a year ago. Loss before income taxes was $15,421,000 against $22,305,000 a year ago. Net loss was $14,854,000 or $0.39 basic and diluted per share against $22,228,000 or $0.59 basic and diluted per share a year ago. The company burned approximately $4.5 million in cash flow from operations for the first 6 months of 2014 inclusive of $1.5 million in cash proceeds from the sale of Hungary entity in the first quarter. This compares to a cash burn of approximately $10.6 million for the same period of 2013. The company is revising its financial guidance for fiscal year 2014. Revenues for 2014 are now expected to total between $35 million and $38 million, representing growth of 10% to 19% compared to the prior year. The company's gross margin is now expected to fall within the range of 70% to 75% as a percentage of total revenues, a significant increase over the level of 54% gross margin delivered in 2013. Finally, the company now expects to achieve positive cash flow from operations for fiscal year 2014.

Codexis, Inc. to Report Q2, 2014 Results on Aug 06, 2014

Codexis, Inc. announced that they will report Q2, 2014 results After-Market on Aug 06, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $2.32 USD -0.06

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $18.07 USD -0.03
Koninklijke DSM NV €47.15 EUR -0.45
Novozymes A/S kr261.80 DKK -0.40
Takasago International Corp ¥492.00 JPY 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at